Point of Care Infectious Disease Testing Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Point of Care Infectious Disease Testing Market is estimated to be valued at USD 6.8 billion in 2024 and is expected to reach USD 13.5 billion by 2031, growing at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031. This significant market expansion reflects increasing demand for rapid, accurate diagnostic solutions that enable timely treatment decisions and improve patient outcomes across various healthcare settings globally.

A key market trend driving this growth is the rising adoption of advanced point-of-care testing technologies, such as molecular diagnostics and biosensors, which offer enhanced sensitivity and faster results. Additionally, the increasing prevalence of infectious diseases, growing awareness of early diagnosis, and favorable government initiatives supporting decentralized testing are fueling market expansion. Integration of digital health tools and real-time data management further optimize testing efficiency, making point-of-care infectious disease testing a critical component of modern healthcare delivery.

Segmental Analysis:

By Test Type: Molecular Testing Driving Precision and Speed in Infectious Disease Diagnosis

In terms of By Test Type, Molecular Testing contributes the highest share of the Point of Care Infectious Disease Testing Market owing to its unparalleled accuracy, rapid turnaround time, and growing clinical acceptance. Molecular testing leverages techniques such as polymerase chain reaction (PCR), enabling the direct detection of pathogen-specific nucleic acids. This precise identification capability is particularly vital in infectious disease management, where early and accurate diagnosis can significantly influence patient outcomes and limit disease transmission. The increasing prevalence of infectious diseases, coupled with the urgent need for expedited testing during outbreaks, has further elevated the demand for molecular diagnostics. Advancements in portable and user-friendly molecular platforms have expanded their deployment beyond centralized laboratories into point of care settings, enhancing accessibility and enabling timely clinical decision-making. Furthermore, the rising focus on personalized medicine and antimicrobial stewardship has facilitated molecular testing adoption, as it delivers pathogen information that guides effective treatment choices without unnecessary antibiotic use. The ability of molecular tests to provide multiplexing options, detecting multiple pathogens simultaneously, enhances their utility across diverse infectious disease presentations. Overall, molecular testing's superior sensitivity and specificity, combined with technological innovations and clinical demand for rapid diagnostic solutions, are key drivers sustaining its dominant share within this segment.

By Technology: Nucleic Acid Amplification Tests (NAAT) Leading Technological Advancements in Rapid Detection

By Technology, Nucleic Acid Amplification Tests (NAAT) hold the largest share of the Point of Care Infectious Disease Testing Market due to their robust capability to rapidly amplify and detect specific genetic material from infectious agents. NAAT methods provide a critical advantage by delivering highly sensitive and specific results within a short timeframe, which is essential for early intervention and controlling infection spread. The high performance of NAAT assays across a broad spectrum of pathogens, including viruses, bacteria, and fungi, enables their widespread applicability in infectious disease diagnostics. Continuous innovation has fostered the development of compact, automated NAAT platforms suitable for decentralized environments such as clinics and emergency care units. This accessibility promotes timely clinical responses and reduces dependency on centralized laboratory infrastructure. Moreover, the increasing emphasis on rapid testing during public health emergencies, such as influenza outbreaks and emerging viral pandemics, has amplified NAAT utilization due to its quick result generation and ease of integration into point of care workflows. Cost-efficiency improvements, streamlined sample preparation, and minimal operator training requirements further accelerate NAAT adoption. The growing clinical preference for molecular-level insights over traditional methods underscores NAAT's technological superiority, positioning it as a cornerstone of the infectious disease point of care testing landscape.

By End User: Hospitals Driving Demand Through Integration and Clinical Complexity

In terms of By End User, Hospitals contribute the highest share of the Point of Care Infectious Disease Testing Market, primarily driven by their central role in managing complex infectious cases and the critical need for rapid diagnostic capabilities within acute care settings. Hospitals witness a high patient influx with diverse and often severe infectious conditions requiring immediate diagnosis to guide therapeutic interventions and infection control measures. The integration of point of care testing within hospital workflows enables clinicians to make timely decisions, reduce the length of hospital stays, and improve patient outcomes. Hospitals also tend to invest heavily in advanced diagnostic technologies and maintain skilled personnel, facilitating the use of sophisticated molecular and immunoassay platforms at the point of care. Additionally, the growing focus on antimicrobial stewardship programs within hospitals reinforces demand for accurate and rapid infectious disease diagnostics, helping minimize hospital-acquired infections and antimicrobial resistance. Emergency departments and intensive care units, in particular, rely on point of care infectious disease tests to expedite care pathways and optimize resource utilization. The rise of hospital networks and coordinated care models further supports standardization and deployment of point of care testing solutions, contributing to sustained growth driven by this end user segment.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Point of Care Infectious Disease Testing Market is driven by a well-established healthcare infrastructure, extensive government support, and a mature ecosystem of diagnostic technology companies. The presence of leading industry players such as Abbott Laboratories, Becton Dickinson and Company, and Cepheid has significantly fueled innovation and accessibility of rapid diagnostic tests. Government initiatives promoting early detection and infectious disease surveillance, especially in the wake of pandemic lessons, have augmented market penetration. Additionally, North America benefits from robust trade policies that facilitate the import and export of advanced diagnostic devices, further strengthening the supply chain and technology dissemination.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth in the Point of Care Infectious Disease Testing Market owing to rising infectious disease prevalence, expanding healthcare access in emerging economies, and increasing public awareness. Rapid urbanization and improvements in healthcare infrastructure, supported by favorable government policies and increasing healthcare expenditure, create conducive conditions for market expansion. Countries such as China, India, and South Korea are witnessing significant investment by both domestic and global companies including Qiagen, Thermo Fisher Scientific, and Wondfo Biotech Co., which focus on developing cost-effective and scalable point-of-care solutions. The diverse market ecosystem, coupled with emerging trade relationships within the region, further accelerates the adoption and distribution of infectious disease testing technologies.

Point of Care Infectious Disease Testing Market Outlook for Key Countries

United States

The United States market remains at the forefront due to robust technological advancements and strong healthcare funding. Major companies such as Abbott, Roche Diagnostics, and Becton Dickinson have pioneered numerous point-of-care testing platforms that are integrated within clinical and emergency care settings. The country's stringent regulatory environment ensures high-quality product offerings, while government health programs emphasizing rapid diagnosis of infectious diseases help maintain strong demand.

China

China's market is rapidly expanding, driven by government investments in healthcare modernization and increasing demand for decentralized diagnostic testing. Domestic companies like Wondfo Biotech and international players such as Thermo Fisher Scientific have enhanced their product portfolios to cater to the large population. Additionally, initiatives promoting digital health and telemedicine have supported the integration of point-of-care testing in remote and rural areas, enhancing accessibility and disease management.

Germany

Germany continues to lead in Europe due to its advanced healthcare system and strong regulatory framework that encourages innovation. Companies such as Siemens Healthineers and Qiagen are instrumental in developing sophisticated infectious disease testing solutions tailored for point-of-care use. Public-private partnerships and government incentives for health technology development boost research efforts, making Germany a hub for diagnostic excellence.

India

India's market is characterized by a growing demand for affordable and rapid diagnostic solutions driven by high disease burden and increasing healthcare outreach. Key players like J Mitra & Co. and international companies such as Abbott are expanding their presence to address the diverse needs of urban and rural populations. Government initiatives aimed at eradicating infectious diseases and improving health infrastructure provide significant support to market growth.

Brazil

Brazil's market benefits from a combination of public health programs targeting infectious disease control and the presence of key multinational companies such as Roche and Abbott. The country's expanding healthcare infrastructure and growing awareness of early diagnostics contribute to greater market uptake. Collaboration between local healthcare providers and diagnostic technology companies facilitates the customization of products suitable for Brazil's unique epidemiological profile.

Market Report Scope

Market Segmentation

Test Type Insights (Revenue, USD, 2020 - 2032)

• Molecular Testing
• Immunoassays
• Microbiological Culture
• Biosensors
• Others

Technology Insights (Revenue, USD, 2020 - 2032)

• Nucleic Acid Amplification Tests (NAAT)
• Lateral Flow Assays
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Next-Generation Sequencing (NGS)
• Others

End User Insights (Revenue, USD, 2020 - 2032)

• Hospitals
• Clinics
• Diagnostic Laboratories
• Pharmacy-Based Testing
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Abbott Laboratories
• Roche Diagnostics
• bioMérieux SA
• Quidel Corporation
• Siemens Healthineers
• Danaher Corporation
• Cepheid Inc.
• Becton, Dickinson and Company
• Thermo Fisher Scientific
• Hologic Inc.
• Canon Medical Systems
• PerkinElmer Inc.
• LumiraDx UK Ltd.
• Trivitron Healthcare
• SD Biosensor, Inc.
• Bio-Rad Laboratories
• OraSure Technologies, Inc.
• Meridian Bioscience